A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas

Exclusion Criteria

• •Subjects are excluded from the study if any of the following criteria apply:
• •1. Treatment with nonpermitted drugs (within 28 days before Day 1).
• •2. Prior treatment with a CD47 or SIRPα targeting agent
• •3. Concurrent anticancer treatments within 28 days before Day 1/first study treatment administration
• •4. Major surgery or significant traumatic injury within 6 weeks prior to Screening or planned major surgery during the study period
• •5. Previous malignant disease other than the target malignancy for this study, except adequately treated Stage I or II cancers from which the subject is currently in complete remission per the Investigator's clinical judgment
• •6. Primary central nervous system (CNS) disease or leptomeningeal disease; known CNS metastases unless treated
• •7. Comorbidities/medical history of any significant diseases that in the judgment of the Investigator would make the subject inappropriate for this study
• •8. Active infection requiring systemic therapy within 14 days before Day 1
• •9. Persisting toxicities Grade \> 1 NCI-CTCAE Version 5.0 related to prior anticancer treatment
• •10. Pregnant or lactating